ERBB2 and breast cancer: Lapatinib, neratinib, and pyrotinib are small HER2 tyrosine-kinase inhibitors that can bind to the ATP site of the receptor intracellular domain, block HER2 dimerization, interfere with signal transduction related to tumor cell proliferation and growth, and display excellent efficacy for HER2+ BC [38].